DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today announced that data and study design details from FORWARD-3 and FORWARD-4, two phase 3 studies of ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD), will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Scottsdale, Ariz. Management will also host a webcast presentation on June 1, 2016 to discuss the data from FORWARD-3 and FORWARD-4, topline results of which were announced in January 2016. ALKS 5461 is a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of MDD in patients who have an inadequate response to standard therapies for clinical depression.
